Acacia Pharma's Byfavo (remimazolam) Receives the US FDA's Approval for the Induction and Maintenance of Procedural Sedation
Shots:
- The safety of BYFAVO was evaluated in 969 patients assessing Byfavo for the induction and maintenance of procedural sedation
- In Jan 2020- the company in-licensed the commercial rights to Byfavo and will pay €30M upfront generated by the approval- consisting of €15M in cash and €15M in ordinary shares of Acacia Pharma stock. Additionally- Acacia will get €10M net cash to launch the product in the US
- Byfavo (remimazolam) is an injection rapid onset/offset IV benzodiazepine sedative for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less- with its expected launch in the US in H2’20
Ref: Acacia Pharma | Image: Acacia Pharma
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com